FMP
NASDAQ
14.82 USD
0.72 (4.86%)
Dr. Frederick G. Vogt Esq., J.D., Ph.D.
Healthcare
Biotechnology
https://www.iovance.com
NASDAQ
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center;...
0001425205
US4622601007
462260100
825 Industrial Road
650 260 7120
US
557
Oct 15, 2010
0001425205
NASDAQ
Biotechnology
Healthcare
462260100
US4622601007
US
14.82
0.62
9.83M
4.14B
-
3.21-18.33
0.2
-
-
-
-
-7.84
-
https://www.iovance.com
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
It looks like there's no news available.